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abstract
BACKGROUND AND OBJECTIVE: Fever during pregnancy has been sus-
pected to harm the developing fetus. However, until now, no systematic
analysis of the available evidence has been undertaken to assess the
impact of maternal fever on health outcomes in the child. The goal of
this study was to systematically review evidence from epidemiologic
studies on adverse health outcomes of the offspring in relation to ex-
posure to maternal fever during pregnancy.
METHODS: Systematic searches in PubMed, Web of Science, and the
Cochrane Library were performed by using Medical Subject Headings,
Boolean operators, and truncation, and references of references were
reviewed. Cohort and case-control studies addressing health outcomes
of prenatal fever exposure in humans were eligible for inclusion.
Studies with no direct reference to fever, studies in selected
populations (eg, preterm births), and studies published before 1990
were excluded.
RESULTS: The available literature supported an increased risk of ad-
verse offspring health in association with fever during pregnancy. The
strongest evidence was available for neural tube defects, congenital
heart defects, and oral clefts, in which meta-analyses suggested
between a 1.5- and nearly 3-fold increased risk with fever exposure
in the ﬁrst trimester. We did not ﬁnd strong evidence of a dose–
response relationship, but there was some evidence that antipyretic
medications may have a protective effect when used in relation to
febrile episodes.
CONCLUSIONS: We found substantial evidence to support the conten-
tion that maternal fever during pregnancy may negatively affect off-
spring health. The harmful effects seemed to cover both short-
and longer-term health outcomes; however, for several outcomes,
the evidence was insufﬁcient to judge any association. Pediatrics
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Fever has for many years been sus-
pected to harm the developing fetus.
Starting in the 1960s, evidence on the
teratogenic effects of hyperthermia
began to accumulate from animal
studies.1,2 Even short exposure to ele-
vated maternal body temperature has
been reported to lead to cell death,
membrane disruptions, vascular dis-
ruptions, and placental infarction, all of
which affect the risk of structural or
functional defects in the offspring.3,4
Studies in animal models provide evi-
dence that prenatal exposure to ele-
vated body temperature, as a marker
of maternal fever, leads to increased
prevalence of various adverse health
outcomes in the offspring. These out-
comes encompass both structural and
functional defects, and they range from
growth retardation, malformations, and
fetal death to longer-term outcomes
such as behavioral alterations and im-
paired cognitive functioning.4,5 These
ﬁndings have been consistent across
a variety of animal species, including
mice, rats, hamsters, guinea pigs, rab-
bits, sheep, pigs, and monkeys.1 Despite
the bulk of evidence supporting a link
between exposure to maternal hyper-
thermia and adverse health outcomes
in animal offspring, however, it remains
unclear whether the experimental con-
ditions under which these associations
have been observed are applicable
to conditions in which humans would
naturally experience hyperthermia,
and hence whether similar associa-
tions would be expected.
Maternal fever is common during
pregnancy. In fact, ∼1 in 5 women re-
port having experienced fever on at least
1 occasion while being pregnant.6–8
Observational epidemiologic studies
have consequently been conducted to
assess potential effects of exposure to
maternal fever on fetal development
and child health. Given the high pro-
portion of pregnant women who are
exposed to fever, even a small increase
in the risk of these outcomes would
make maternal fever a public health
concern. We identiﬁed 1 previous pub-
lication that reviewed the literature on
the impact of hyperthermia on neural
tube defects.9 However, up until now,
no systematic analysis has been un-
dertaken to assess the impact of ma-
ternal fever on a broader spectrum of
health outcomes in human offspring.
Thus, the aim of the present article was
to systematically review existing evi-
dence from epidemiologic studies on
the associations between maternal fe-
ver during pregnancy and adverse
health outcomes in the child.
METHODS
The Preferred Reporting Items for
Systematic Reviews and Meta-analyses
statement10 was used as a reporting
guideline for this review.
Identiﬁcation of Studies
To identify relevant studies for inclusion
in the review, we applied a 2-stage
search strategy. First, we systematical-
ly searched bibliographic databases
(PubMed, Web of Science, and the
Cochrane Library) by using Medical
Subject Headings, Boolean operators,
and truncation. We searched in titles,
abstracts, topics, and key words
depending on the database, and applied
limits restricting the search to studies
published in 1990 or later and to human
studies. Search words included fever,
febrile, hyperthermia, pyrexia, preg-
nancy, pregnant women, and gestation.
Second, we used a snowballing tech-
nique, inwhichwepursued references of
references, to detect reports of studies
not found in thedatabase search. Studies
were initially identiﬁed based on title and
abstract and later included through full-
text evaluation. The latest search was
conducted in August 2013.
Study Eligibility
Cohort and case-control studies address-
ing health outcomes of prenatal fever
exposure in humans were eligible for in-
clusioninthereview.Studieswereincluded
only if theymadedirectreferencesto fever;
that is, by addressing fever directly or al-
ternatively by addressing febrile illnesses
as a proxy for fever. We excluded studies
in selected populations (eg, studies
addressing only preterm births) and
studies in which the report was in-
adequate to thoroughly evaluate the
methods and results. In addition, we
chose to limit the review to more recent
evidence, including only studies pub-
lished since 1990 until August 2013. We
excluded duplicate publications and
studieswith inadequate assessment of
fever or those in which we could not
distinguish prenatal fever exposure
from fever in relation to labor. The
criteria used to include and exclude
studies in the review are illustrated in
Fig 1.
Data Extraction
Information on reference, publication
date, design, study population, sample
size, feverassessment, exposureperiod
of interest, outcomeconsidered, overall
effect estimates, and estimates for
varying fever intensities and for an-
tipyretic use was extracted. Because
several of the studies included a variety
of analyses on fever exposure, we ap-
plied the following decision rules for
extraction of effect estimates. First,
wheneverresults incase-control studies
were presented for .1 comparison
group, we always chose estimates from
comparisons with matched control
subjects over general population con-
trol subjects, and general population
control subjects over malformed con-
trol subjects. Second, when both crude
and adjusted measures were available,
we chose adjusted measures, with the
exception of the studies that were in-
cluded in meta-analyses. For these,
crudemeasureswere applied to ensure
comparability of studies. Finally, if
a study speciﬁed a certain exposure
period of interest (eg, ﬁrst-trimester
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exposure), we chose estimates pertain-
ing to this time period.
Evidence Rating
The risk of bias of included studies
was assessed by using the Newcastle-
Ottawa Scale,11 as recommended by
Deeks et al.12 Risk of bias in relation to
selection, comparability, and assess-
ment of the exposure/outcome was
assessed according to 9 items by using
a star allocation scheme. Stars were
allocated if a study was deemed to have
a low risk of bias within each item,
according to the coding manual pro-
vided.13 A study was categorized as
being of low risk of bias if a total of 8 to
9 stars were allocated, medium risk of
bias if 6 to 7 stars were allocated, and
of high risk of bias if the study was
given #5 stars.
Data Synthesis
To quantitatively combine results of
studies addressing the same outcome,
meta-analyses were performed by us-
ing Stata version 13 (Stata Corp, College
Station, TX)14 when $4 studies were
eligible for inclusion. Statistical het-
erogeneity was assessed by using the
Cochran’s x2 statistic. When studies
were homogeneous, we applied a
Mantel-Haenszel ﬁxed-effects model;
the DerSimonian and Laird random
effects model was used when studies
were heterogeneous. Studies not suit-
able for inclusion in meta-analyses
were presented in a table, according
to the outcome of interest. No summary
measures were calculated for these
studies, however, as they were too
heterogeneous in terms of methods
and the outcomes addressed. Lastly,
we summarized studies addressing
the effects of temperature elevation as
well as of antipyretic use.
RESULTS
Seventy-eight potentially eligible stud-
ies were identiﬁed through systematic
searches in relevant databases or
through reference reviews. Based on
the full-text evaluation, 32 studies were
excluded. The main reasons for exclu-
sion were inadequate assessment or
reportingof feverexposure, inadequate
description of the study, and duplicate
analyses across different publications.
A total of 46 studies were included in
the review.
The characteristics of included studies
are summarized in Table 1.6,7,15–58
Studies varied in size from∼100 to 100 000
observations, and approximately one-
half of the reports were based on
samples of$4000 observations. With 1
exception,18 fever was measured as
maternal self-reported episodes of fe-
ver or febrile illness, with or without
speciﬁc subquestions concerning
number of episodes, maximum tem-
perature, duration of fever, accompa-
nying symptoms or illness, timing of
exposure, and use of antipyretic
measures to treat the fever. The studies
considered fever exposures from up to
3 months before conception through
the entire pregnancy; however, the
majority of the studies considered
primarily ﬁrst-trimester exposures.
This choice was a reﬂection of the
outcomes considered in the studies, as
a large proportion of included studies
addressed birth defects in which the
critical developmental period is con-
sidered to be early in pregnancy. In
general, the prospective cohort studies
tended to be of lower risk of bias com-
pared with case-control studies. Within
case-control studies, the population-
based studies were generally classi-
ﬁed with a lower risk of bias compared
with the nonpopulation-based studies.
Fever and Health Effects in the
Child
Associations between exposure to ma-
ternal fever and a variety of health
outcomes were addressed in the in-
cluded studies. A substantial proportion
of studies considered shorter-term
health effects, such as adverse preg-
nancy outcomes and birth defects,
whereas a smaller proportion in-
vestigated the post-neonatal health
effects, such as allergic diseases, de-
velopmental outcomes, and offspring
FIGURE 1
Flow diagram illustrating selection of studies.
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mortality. Random effects meta-analyses
were conducted for case-control studies
on neural tube defects (n = 9) and oral
clefts (n = 5), due to statistical hetero-
geneity, whereas a ﬁxed-effects meta-
analysis was conducted for studies on
congenital heart defects (n= 7). All of the
studies included in the meta-analyses
were restricted to preconceptional and
ﬁrst-trimester fever exposure. Results
are presented in forest plots in Figs 2, 3,
and 4. Maternal fever exposure was
signiﬁcantly associated with an in-
creased risk of all 3 birth defects. How-
ever, the effect was strongest in relation
to neural tube defects (odds ratio
[OR]pooled: 2.90 [95% conﬁdence interval
(CI): 2.22–3.79]) compared with oral
clefts (ORpooled: 1.94 [95% CI: 1.35–2.79]),
and congenital heart defects (ORpooled:
1.54 [95% CI: 1.37–1.74]). Meta-analyses
were performed exclusively on case-
control studies to increase homogene-
ity. Cohort and case-control studies differ
in relation to their risk of bias due to
selection and differential recall. With
regard to neural tube defects, 1 cohort
study was consequently not included in
the meta-analysis.25 In this study, how-
ever, a somewhat lower and insigniﬁcant
increased risk of neural tube defectswas
reported (OR: 1.8 [95% CI: 0.8–4.1]). Fur-
thermore, sensitivity analyses, excluding
studieswith high risk of bias,35,48 showed
only slightly lower pooled estimates,
which remained statistically signiﬁcant
(data not shown).
Fewer studies were available for each
remaining health outcome. The overall
estimates of the impact of maternal
fever exposure are presented in Table 2
for each study, ordered from short- to
longer-term effects in the child. With 2
exceptions,27,55 studies on pregnancy
outcomes (ie, spontaneous abortion,
stillbirth, preterm birth, birth weight)
found no association with maternal
fever exposure. For birth defects, con-
versely, several studies suggested that
fever exposure is associated with
excessive risk. Although Acs et al,35
Zhang and Cai,50 and Erickson48 sug-
gested that the risk of any birth defect
is increased by ∼40% to 60% for those
children exposed to maternal fever
during the ﬁrst trimester, Chambers
et al24 suggested an even higher, al-
though not signiﬁcant, risk for major
malformations. Although these esti-
mates may be driven by neural tube
defects, congenital heart defects, and
oral clefts, as suggested by the meta-
analyses, associations were also
reported for several other birth
defects, including ear defects,33 anorectal
malformations,52 renaldefects,43 cataract,36
and limb deﬁciencies.44 Other stud-
ies reported no signiﬁcantly increased
risk for several of the same out-
comes.24,26,35,54 The evidence of an
association with birth defects other
than neural tube defects, congenital
FIGURE 2
Forest plot of case-control studies considering maternal fever and risk of neural tube defects in the
offspring.
FIGURE 3
Forest plot of case-control studies consideringmaternal fever and risk of heart defects in the offspring.
REVIEW ARTICLE
PEDIATRICS Volume 133, Number 3, March 2014 e679
by guest on February 12, 2017Downloaded from 
heart defects, and oral clefts is there-
fore limited, as most defects were only
investigated in 1 or 2 populations, and
results seemed to be inconsistent be-
tween the studies.
For allergic diseases, 2 studies report
an approximately twofold increased
risk of asthma in children exposed
to maternal fever,20,53 whereas another
study found no association with
wheezing, eczema, or atopic sensitiza-
tion.22 Signiﬁcant longer-term effects
on the child development of exposure
to maternal fever were also reported,
however, with estimates in general
closer to unity. In 3 studies on child-
hood autism16,56 and autism spectrum
disorders,38 an increased risk was
observed in relation to fever exposure.
Increased risks were also reported
for cerebral palsy,15,49 developmental
delay,38 various behavior character-
istics,19 decreased academic perfor-
mance,19 and psychosis.57 No overall
association was reported for epi-
lepsy17 or schizophrenia,21 however. In
addition, 1 study23 in women infected
with varicella-zoster virus found no
increased risk of neurobehavioral def-
icits after fever in relation to the
infection. Lastly, 1 study considered
overall mortality and found that ma-
ternal febrile episodes signiﬁcantly
increased the mortality rate in the
offspring in male subjects but not in
female subjects.18
When we considered effect sizes
reported across different health
effects, we found that studies which
were conducted prospectively were
more likely to report lower risk esti-
mates compared with studies with
retrospective assessment of fever and
also more likely to ﬁnd no effects of
fever. Likewise, studies with lower risk
of bias were also more likely to report
lower risk estimates compared with
studies with higher risk of bias.
Risk in Relation to Level of Fever
Fever intensity, measured by the max-
imum temperature during a fever epi-
sode, was hypothesized in several
studies to affect the strength of the
association with the outcome of in-
terest. Studies reporting estimates for
different fever intensities are summa-
rized in Table 3. Chambers et al24
reported nonsigniﬁcant increases in
the risk of several minor birth defects
with increasing intensity of fever.
However, none of the remaining
studies7,16,17,40,41 reported such a
temperature–response relationship.
Antipyretic Medication
Studies that investigated whether the
use of antipyretic medication attenu-
ated the risk related to maternal fever
exposure are presented in Table 4.
One study30 reported that use of anti-
pyretics was associated with an in-
creased risk of the given outcome
compared with the risk observed with
fever alone. This tendency is supported
by another study by Wang et al29
(not presented in Table 4; relevant
numbers were not reported). In con-
trast, several other studies observed
reductions in risk with antipyretic
medication.34,35,38–40,42,46,47 In some cases,
the risk associated with fever was even
eliminated.35,36,40
DISCUSSION
Our review shows that the available
literature supports the occurrence of
adverse health impacts in association
with fever. The strongest evidence is
available for effects on the following
selected birth defects: neural tube
defects, congenital heart defects, and
oral clefts, in which pooled estimates
suggest betweena1.5- andnearly 3-fold
increased risk through exposure to
maternal fever during the ﬁrst tri-
mester. Some, but not all, evidence
furthermore supports an association
with other birth defects, developmental
deﬁcits, and overall mortality. However,
despite the numerous studies reporting
associations between fever and ad-
verse health outcomes, we found no
strong evidence to suggest that these
associations were subject to a dose–
response relationship. In addition, we
found that most studies, but not all,
suggested a protective effect of anti-
pyretic medications when used in
relation to febrile episodes. To our
FIGURE 4
Forest plot of case-control studies considering maternal fever and risk of oral clefts in the offspring.
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knowledge, this is the ﬁrst review that
systematically assesses and synthe-
sizes studies on the entire spectrum of
adverse health outcomes in the child
after fever exposure during pregnancy.
Although there was evidence of an ad-
verse impact of fever on several health
outcomes, the strength of this evidence
varied considerably. For neural tube
defects, congenital heart defects, and
oral clefts, several studies were avail-
able, enabling us to calculate pooled
estimates based on meta-analyses. The
ﬁndings of increased risks related
to prenatal fever exposure remained
statistically signiﬁcant even when
studies with a high risk of bias were
excluded. For other birth defects, al-
lergic diseases, and for developmental
deﬁcits, the evidencewas limited due to
fewer studies addressing each out-
come, varying risk of bias, and a higher
degree of inconsistency between study
ﬁndings. The associations found in
studies reporting an adverse effect of
fever are nevertheless generally con-
sistent with effects reported from ani-
mal studies.1 One ﬁnding that did
contrast with evidence from animal
studies, however, was the fairly con-
sistent suggestion that fever had no
effect on the risk of adverse pregnancy
outcomes (spontaneous abortion,
stillbirth, and preterm delivery). It is
unclear why no association was ob-
served for these very short-term out-
comes as these are some of the most
frequently reported adverse outcomes
in animal studies.3 It may be that the
extent of increased body temperature
experienced by women during a fever
is not sufﬁcient to cause such severe
harm that it leads to fetal death. Gen-
erally, it is suggested that maternal
body core temperature can be raised
by ∼2°C or more before risk of fetal
death is increased.2 This increase is
equivalent to a fever of $39°C. How-
ever, both the study by Chambers et al24
and that by Andersen et al7 performedTA
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subanalyses restricted to women with
temperatures of $38.9°C, but the
risk remained unchanged. Another ex-
planation could be that prospective
studies addressing adverse pregnancy
outcomes, such as spontaneous abor-
tion, did not recruit the pregnant
women in time to catch most of the
very early pregnancy losses and con-
sequently found no overall effect.
In the reviewed studies, we also found
little evidence to support a dose–
response relationship with tempera-
ture. This evidence was based on
studies assessed to be of low and me-
dium risk of bias. The absence of a
dose–response relationship contrasts
with ﬁndings from animal studies and
also seems counterintuitive if a causal
relationship between fever and ad-
verse health outcomes exists. It could
possibly be explained by the fact that
the studies used self-reported mea-
sures of the maximum temperature
during a febrile event, and such a
measure is likely to be imprecise sev-
eral weeks or even months after the
episode occurred. Furthermore, ther-
mal dose is not only deﬁned by the el-
evation of temperature but also by the
duration of the exposure. It might
therefore be necessary to consider
both temperature elevation and fever
duration in combination when looking
for a dose–response relationship. This
theory is supported in the study by
Chambers et al,24 who deﬁned a high
fever group by using both temperature
elevation and duration. This study was
the only 1 of 6 reported in Table 3 that
found a dose–response relationship
for several minor birth defects. An in-
creased risk by increasing duration
of the fever alone (ie, without consid-
ering temperature elevation) was also
reported by Atladóttir et al16 and
Suarez et al42 but not by Sun et al17 or
Andersen et al.7
On the basis of studies with varying
risks of bias, we also found evidence to
suggest that antipyretic use seemed
to attenuate the risks associated with
fever exposure. Only 2 of 10 studies
reported increased risk associated
with antipyretic use in relation to a fe-
brile episode.29,30 Nevertheless, sub-
stantiallymore studies reported results
suggesting that antipyretic use de-
creased the risk associated with fever
exposure. Differences between study
ﬁndings may be due to differences in
the type of antipyretic agents commonly
used, as this use can vary between
countries.30 The fact that a reduction or
removal of the fever generally seems to
decrease the risk of a given outcome
supports the notion that fever itself
carries a risk and, furthermore, that
this risk is distinct from a potential risk
associated with the infection causing
the fever. It also provides the possibility
of preventing occurrence of adverse
health effects in the child, if fever is
readily treated in pregnant women.
Nevertheless, some antipyretic agents
have also been suspected of having
detrimental effects on the fetus,59 and
more research is needed to be able to
identify safe choices of antipyretics and
to estimate if potential risks of antipy-
retic use outweigh the beneﬁts of
reduced temperature. One potential
concern about the studies investigating
the effect of antipyretic use was that
several studies did not specify whether
the antipyretic medication was taken as
a measure to treat fever. Most antipy-
retic medications have other purposes
in addition to fever management, and
it is possible that they were used as
analgesics instead. If the antipyretics
were generally used in relation to the
underlying infection and not at the time
of the fever, it would dilute the measure
of effect. Only 3 studies30,38,46 clearly
stated that the antipyretics were taken
TABLE 4 Effect of Fever During Pregnancy With or Without Use of Antipyretic Agents
Ref. Author Outcome Fever Without
Antipyretics
Fever With
Antipyretics
Effect of Antipyretic Use
aOR 95% CI aOR 95% CI
Birth defects
30 Li et al, 2007 Neural tube defects 4.0 2.5–6.5 13.9 3.0–63.6 ↑ risk
35 Acs et al, 2005 Neural tube defects 2.7 1.8–4.0 0.7 0.3–1.6 ↓ riska
42 Suarez et al, 2004 Neural tube defects 3.9 1.5–10.0 2.4 1.1–5.4 ↓ risk
46 Shaw et al, 1998b Neural tube defects 2.9 1.8–4.8 1.3 0.8–2.2 ↓ riska
39 Oster et al, 2011 Right-sided obstructive defects 2.4 1.3–4.3 1.5 0.9–2.4 ↓ risk
35 Acs et al, 2005 Heart defects 1.7 1.3–2.2 1.4 0.9–2.1 ↓ risk
40 Hashmi et al, 2010 Oral clefts 1.8 1.2–2.8 1.1 0.9–1.5 ↓ riska
35 Acs et al, 2005 Cleft lip 6 palate 3.3 2.4–4.7 1.4 0.8–2.5 ↓ riska
34 Czeizel et al, 2007 Multiple congenital abnormalities 2.2 1.7–2.9 1.6 0.9–2.9 ↓ risk
36 Vogt et al, 2005 Congenital cataract 11.1 5.3–23.3 0.6 0.1–4.0 ↓ riska
Developmental deﬁcits
38 Zerbo et al, 2013 Autism spectrum disorders 2.6 1.3–5.0 1.3 0.6–2.8 ↓ risk
Developmental delay 2.7 1.2–6.3 2.1 0.8–5.4 ↓ risk
aOR, adjusted odds ratio.
a Signiﬁcant differences between risk estimates for fever exposure with or without antipyretic use.
b Estimates are calculated based on numbers presented in the original article (crude estimates).
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as a measure to treat the fever; how-
ever, no systematic differences in effect
estimates or SEs were seen between
these and the remaining studies.
There are several mechanisms through
which fever has been proposed to in-
terfere with fetal development. When
infection in pregnancy occurs, the
maternal immune system is mobilized,
causing changes in the level of cyto-
kines in the fetal environment. Some
cytokines, such as interleukin 1, in-
terleukin 6, and tumor necrosis factor-
a, are pyrogenic, causing hyperthermia
to occur through alteration of the set
point in the hypothalamus.60 Hypothe-
sized effects of the increased body
temperature include interruption of
protein synthesis and enzyme pro-
duction, which results in cellular pro-
cesses (eg, proliferation, migration,
differentiation, apoptosis) becoming
altered or dysfunctional.4,60 In addition,
as a reaction to the fever, the heat shock
response is induced.2 The response acts
as a survival mechanism, and the ex-
pression of heat shock proteins is in-
creased to enhance cellular resistance
to thermal stress.60 The heat shock re-
sponse takes precedence over other
cellular activities, resulting in inhibition
of protein synthesis and cell pro-
liferation.4 It is consequently believed
that these mechanisms may disturb
or harm the fetal development if they
coincide with speciﬁc windows of
vulnerability.
From animal studies, we know that
different defects hold unique windows
of vulnerability. Although some of the
studies included in the review consid-
ered fever exposure in speciﬁc periods
of the pregnancy, others considered the
entire pregnancy. Detrimental effects of
prenatal exposure to fever might be
diluted if too-broad time intervals of
exposure are used in the analyses.
Czeizel et al61 suggested that future
research in this area should consider
critical exposure periods as speciﬁc as
possible to the outcome of interest and
not rely only on commonly used indi-
cators of time, such as trimesters. We
found most evidence to support a
harmful effect of fever in the early
stages of pregnancy. The majority of
the studies, however, also only consid-
ered these early exposures, which
were related to their outcomes of in-
terest (namely, birth defects). Whether
exposure later in pregnancy is harmful
was less studied. Both the studies by
Dombrowski et al19 and by Calvani
et al,53 however, suggest that expo-
sures in middle and late pregnancy
may lead to longer-term adverse
effects in the child. Nevertheless, the
current evidence is insufﬁcient to con-
cludewhether fevermight be harmful in
all stages of pregnancy.
It is well established that several
infections, such as the TORCH complex
(toxoplasmosis, other vertically trans-
mitted infections, rubella, cytomegalo-
virus, herpes simplex virus 2), have
teratogenic effects.62,63 In addition, a
range of other infections (eg in-
ﬂuenza,64 Q fever,65,66 HIV67) are sus-
pected of having detrimental effects on
the child. Because fever occurs as
a response to infection, it is problem-
atic to distinguish the effects of fever
from those of an underlying infection
and also from the potential treatment
of the infection or the fever. These
concerns should be kept in mind when
interpreting the ﬁndings of the present
review. However, because the aim was
to summarize studies discussing pre-
natal exposure to fever as a potential
threat to the child, we have not in-
cluded studies on infections only.
Instead, only studies with a direct ref-
erence to fever were considered. Con-
sequently, we included studies that
deﬁned fever by using speciﬁc ques-
tions on fever but also whenever
authors deﬁned an infection as being
a febrile illness. The concept of a fe-
brile infection is only vaguely deﬁned,
however, and studies considered
infections from inﬂuenza, in which
∼90%35 experience fever, to infections
such as the common cold, in which
fever might only be present in ∼50%68
of cases. If an infection in which fever
only occurs in one-half of the cases is
used as a proxy for fever, it would
lead to substantial misclassiﬁcation of
the fever exposure. Because this mis-
classiﬁcation is most likely unrelated
to the outcomes, it would be un-
systematic (nondifferential), suggest-
ing that studies using febrile infections
as a measure of fever would, in most
cases, underestimate the impact of
fever.
Another concern in systematic reviews
is the potential for publication bias, and
we cannot exclude the possibility that
this factor could have affected the
ﬁndings of this review. In addition,
a number of studies were found to have
a medium or high risk of bias, when
assessed by using the Newcastle-
Ottawa Scale. A general problem for
a large proportion of the studies was
the potential for bias in the assessment
of fever. Several of the ﬁndings were
based on case-control studies that have
assessed fever exposure only after the
presence or absence of the outcome
was recognized. Compared with cohort
studies, case-control studies are more
prone to biases originating from dif-
ferential recall for case and control
mothers as well as from selection. We
observed that, across different health
outcomes, studiesusingaretrospective
design were more likely to report
higher risks compared with studies
using aprospective design,which could
suggest that pooled estimates from the
meta-analyses, as well as individual
results of case-control studies, were
subject to positive bias. Several of the
case-control studies did also try to
overcome problems in relation to se-
lection bias, by using a population-
based design, to ensure that control
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subjects reﬂected the population that
gave rise to the cases. Some studies
also performed sensitivity analyses by
using malformed control subjects to
assess the extent of recall bias. Li et al,30
Lynberg et al,47 and Medveczky et al37
found smaller effects when they used
a malformed comparison group; how-
ever, the associations were always in
the same direction and remained sta-
tistically signiﬁcant.
CONCLUSIONS
We found substantial evidence to sup-
port an adverse impact of maternal
fever during pregnancy. The harmful
effects seemed to cover both some
short- and longer-term health out-
comes. With this review, we do not have
adequate evidence, however, to rule out
or conﬁrm associations with many of
the investigated outcomes. Prospective
studies are therefore now required to
investigate whether the ﬁndings from
case-control studies on birth defects
remain valid when the exposure to
fever is assessed before the outcome
occurs. Researchon longer-termhealth
impacts is also still in its infancy, but
several of the studies included in the
review indicate that this is a relevant
area of further research. In addition,
we suggest that further research
aspires to clarify the impact of timing,
duration, and extent of fever, as well
as the potential role of antipyretic
agents.
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